Scholarlink

<p>Triple-negative breast cancer (TNBC), which lacks targeted treatment options, continues to pose a major clinical hurdle. This study investigated the molecular complexities of TNBC, with a focus on m7G modifications, the immune microenvironment, and their influence on patient prognosis. An integrated analysis of m7G-related genes facilitated the creation of a risk model based on differentially expressed m7G-related genes, which effectively stratified patients with TNBC into low- and high-risk groups, with the low-risk group demonstrating a marked survival advantage. Immune cell infiltration analysis revealed substantial differences between risk groups, suggesting a potential association between m7G-related risk and immune landscape modulation. Genomic profiling identified distinct mutational patterns, with TP53 mutations predominant in the high-risk group and PIK3CA mutations in the low-risk group. Chemosensitivity analysis indicated the potential for tailored drug responses, highlighting the utility of the m7G-related risk score in guiding personalized therapeutic approaches. Additionally, a nomogram incorporating the risk score, stage, and M stage was developed, providing a valuable tool for predicting 3-, 5-, and 10-year survival probabilities.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

m7G-related gene signatures determine prognosis in triple-negative breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月27日

查看全文
  • Yunxiang Li,
  • Xin Lan,
  • Jianqiao Dong,
  • Jing Li,
  • Bin Wang,
  • Yanhong Wang,
  • Hongyan Jia

摘要

Triple-negative breast cancer (TNBC), which lacks targeted treatment options, continues to pose a major clinical hurdle. This study investigated the molecular complexities of TNBC, with a focus on m7G modifications, the immune microenvironment, and their influence on patient prognosis. An integrated analysis of m7G-related genes facilitated the creation of a risk model based on differentially expressed m7G-related genes, which effectively stratified patients with TNBC into low- and high-risk groups, with the low-risk group demonstrating a marked survival advantage. Immune cell infiltration analysis revealed substantial differences between risk groups, suggesting a potential association between m7G-related risk and immune landscape modulation. Genomic profiling identified distinct mutational patterns, with TP53 mutations predominant in the high-risk group and PIK3CA mutations in the low-risk group. Chemosensitivity analysis indicated the potential for tailored drug responses, highlighting the utility of the m7G-related risk score in guiding personalized therapeutic approaches. Additionally, a nomogram incorporating the risk score, stage, and M stage was developed, providing a valuable tool for predicting 3-, 5-, and 10-year survival probabilities.